Revenue Breakdown
Composition ()
No data
Revenue Streams
BioCardia Inc (BCDA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reconstructive Division, accounting for 92.7% of total sales, equivalent to $521.00K. Another important revenue stream is Spine Division. Understanding this composition is critical for investors evaluating how BCDA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, BioCardia Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -317.47%, provide a clear picture of how effectively BCDA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BCDA competes directly with industry leaders such as BON and NCEL. With a market capitalization of $13.69M, it holds a significant position in the sector. When comparing efficiency, BCDA's gross margin of N/A stands against BON's 24.00% and NCEL's N/A. Such benchmarking helps identify whether BioCardia Inc is trading at a premium or discount relative to its financial performance.
